{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:23:14Z","timestamp":1789899794637,"version":"4.0.1"},"reference-count":63,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Roche Innovation Center, F. Hoffmann-La Roche"},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201400006C"],"award-info":[{"award-number":["HHSN272201400006C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Current influenza treatment relies on a single class of antiviral drugs, the neuraminidase inhibitors (NAIs), raising concern over the potential emergence of resistant variants and necessitating the development of novel drugs. In recent years, investigational inhibitors targeting the endonuclease activity of the influenza acidic polymerase (PA) protein have yielded encouraging results, although there are only limited data on their\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy. Here, we examined the antiviral potential of the PA endonuclease inhibitor RO-7 in prophylactic and therapeutic regimens in BALB\/c mice inoculated with influenza A\/California\/04\/2009 (H1N1)pdm09 or B\/Brisbane\/60\/2008 viruses, which represent currently circulating antigenic variants. RO-7 was administered to mice intraperitoneally twice daily at dosages of 6, 15, or 30 mg\/kg\/day for 5 days, starting 4 h before or 24 or 48 h after virus inoculation, and showed no adverse effects. Prophylactic administration completely protected mice from lethal infection by influenza A or B virus. The level of therapeutic protection conferred depended upon the time of treatment initiation and RO-7 dosage, resulting in 60 to 100% and 80 to 100% survival with influenza A and B viruses, respectively. RO-7 treatment significantly decreased virus titers in the lung and lessened the extent and severity of lung damage. No PA endonuclease-inhibitor resistance was observed in viruses isolated from lungs of RO-7-treated mice, and the viruses remained susceptible to the drug at nanomolar concentrations in phenotypic assays. These\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy results further highlight the potential of RO-7 for development as antiviral therapy for influenza A and B virus infections.\n          <\/jats:p>","DOI":"10.1128\/aac.02460-16","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T01:55:24Z","timestamp":1487037324000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses"],"prefix":"10.1128","volume":"61","author":[{"given":"Jeremy C.","family":"Jones","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindumadhav M.","family":"Marathe","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vogel","sequence":"additional","affiliation":[{"name":"Veterinary Pathology Core, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Gasser","sequence":"additional","affiliation":[{"name":"Roche Innovation Center, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Najera","sequence":"additional","affiliation":[{"name":"Roche Innovation Center, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Govorkova","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Influenza","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. 2008. Influenza. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/immunization\/topics\/influenza\/en\/."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.824709"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.05.023"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/507558"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.12160"},{"key":"e_1_3_3_7_2","volume-title":"Key facts about seasonal flu vaccine","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. 2015. Key facts about seasonal flu vaccine. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/flu\/protect\/keyfacts.htm#benefits."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00502-2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2013.121"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.02.005"},{"key":"e_1_3_3_11_2","volume-title":"Antiviral drugs","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. 2015. Antiviral drugs. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/index.htm."},{"key":"e_1_3_3_12_2","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore AE","year":"2011","unstructured":"Fiore AE FryA ShayD GubarevaL BreseeJS UyekiTM, Centers for Disease Control and Prevention. 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza\u2014recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep60:1\u201324.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.05.004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12176"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12462"},{"key":"e_1_3_3_16_2","volume-title":"Antiviral drug resistance among influenza viruses","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. 2015. Antiviral drug resistance among influenza viruses. Centers for Disease Control and Prevention, Atlanta, GA. http:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/antiviral-drug-resistance.htm."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2101.141006"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.08.023"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.842466"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S36601"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002830"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14009"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21401"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2015.03.017"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990208"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1421"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw194"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00125-11"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/adt.2015.668"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986611796378675"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12107"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2011.08.007"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.03.013"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04623-14"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7665"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07745"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-44"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.095588"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07720"},{"key":"e_1_3_3_40_2","doi-asserted-by":"crossref","unstructured":"Jones\nJC MaratheBM LernerC KreisL GasserR PascuaPN NajeraI GovorkovaEA. 2016. A novel endonuclease inhibitor exhibits broad-spectrum anti-influenza activity in vitro. Antimicrob Agents Chemother60:5504\u20135514. doi:10.1128\/AAC.00888-16.","DOI":"10.1128\/AAC.00888-16"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1304"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep22880"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01579-07"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2723-2732.2001"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2008.73"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv331"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.12.010"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.13.35"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.12.014"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmod.2004.01.003"},{"key":"e_1_3_3_51_2","volume-title":"Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/2016_17_north\/en\/."},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.18.8989-9001.2002"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(89)90615-6"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519772113"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00832-13"},{"key":"e_1_3_3_56_2","volume-title":"Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults: T705US316","author":"ClinicalTrials.gov","year":"2015","unstructured":"ClinicalTrials.gov. 2015. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults: T705US316. National Institutes of Health, Bethesda, MD. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02026349?term=favipiravir+influenza&rank=2."},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2016.08.003"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1615-2"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.14.30"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00159-10"},{"key":"e_1_3_3_61_2","first-page":"493","article-title":"A simple method for estimating fifty percent endpoints","volume":"27","author":"Reed LM","year":"1938","unstructured":"Reed LM MuenchH. 1938. A simple method for estimating fifty percent endpoints. Am J Hyg27:493\u2013497.","journal-title":"Am J Hyg"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2010.12.014"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/mst197"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006419107"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02460-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02460-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:58:37Z","timestamp":1645477117000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02460-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1128\/AAC.02460-16"],"URL":"https:\/\/doi.org\/10.1128\/aac.02460-16","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"2016-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02460-16"}}